150 related articles for article (PubMed ID: 37306182)
21. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
[TBL] [Abstract][Full Text] [Related]
22. Vortex keratopathy associated with ribociclib.
Türkel A; Özdoğan S; Yekedüz E; Şeyran E; Karaçin C; Ateş Ö
J Oncol Pharm Pract; 2023 Jan; 29(1):230-232. PubMed ID: 35570741
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
24. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
25. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
De Laurentiis M; Caputo R; Mazza M; Mansutti M; Masetti R; Ballatore Z; Torrisi R; Michelotti A; Zambelli A; Ferro A; Generali D; Vici P; Coltelli L; Fabi A; Marchetti P; Ballestrero A; Spazzapan S; Frassoldati A; Sarobba MG; Grasso D; Zamagni C
Target Oncol; 2022 Nov; 17(6):615-625. PubMed ID: 36152144
[TBL] [Abstract][Full Text] [Related]
27. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
28. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
29. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
Fu F; Kano J; Ma J; Guindy M
Curr Oncol; 2022 Mar; 29(3):1761-1772. PubMed ID: 35323345
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Yardley DA; Hart L; Favret A; Blau S; Diab S; Richards D; Sparano J; Beck JT; Richards P; Ward P; Ramaswamy B; Tsai M; Blackwell K; Pluard T; Tolaney SM; Esteva FJ; Truica CI; Alemany C; Volas-Redd G; Shtivelband M; Purkayastha D; Dalal AA; Miller M; Hortobagyi GN
Clin Breast Cancer; 2019 Aug; 19(4):268-277.e1. PubMed ID: 31160171
[TBL] [Abstract][Full Text] [Related]
32. Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
Rudlowski C; Beermann N; Leitzen L; Nuding B
Breast Care (Basel); 2020 Jun; 15(3):289-293. PubMed ID: 32774224
[TBL] [Abstract][Full Text] [Related]
33. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
34. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
[TBL] [Abstract][Full Text] [Related]
35. Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.
Abdel-Razeq H; Sharaf B; AlMasri R; Abdel-Razeq R; Tamimi F; Khader O; Salama O; Abunasser M; Edaily S; Abdulelah H
Cancer Manag Res; 2022; 14():1033-1041. PubMed ID: 35300061
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report.
Sun M; Cai L; Chen M
Medicine (Baltimore); 2023 Jun; 102(24):e33975. PubMed ID: 37327257
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
38. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
39. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.
Loi S; Karapetis CS; McCarthy N; Oakman C; Redfern A; White M; Khasraw M; Doval DC; Gore V; Alam M; Binko J; Lu DR; Kim S; Boyle F
Asia Pac J Clin Oncol; 2022 Dec; 18(6):560-569. PubMed ID: 34908235
[TBL] [Abstract][Full Text] [Related]
40. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
